gottlieb. you are pretty regulars at that table. this december will mark the two-year anniversary of the 21st century cures act being signed into law by president obama and his last public signing ceremony. the promise of the 21 current ri cures is to advance the discovery and development of new treatments, cures through increased research and improve drug approval process. this important law dedicated $6.3 billion in new investments to support medical research initiatives like the bo biden cancer moon shot, the brain initiative, the precision medicine initiative within the national institute of health, it also provides money to food and drug administration to advance the agency's mission and implement the policies in the underlying bill. i hope our committee and congress that these investments are being put toward finding a cure and ensuring the infrastructures is in place so that new their piece are accessible to all americans. the in. ih has provided $4.8 billion in new funding and advanced

and doctor gottlieb thank you for your comments. i always felt like while we were doing the roundtables for these cures this is where the big money was and if we could reduce the time in trials and reduce, if a product was going to fail we would allow it to be identified to see if it will fail early, facing something that was not going to pan out, i would really like the concept about the seamless trial concept. the time between phase i, phase ii, and phase 3 clinical trial i think it's likely to have a significant impact for the things that have always concerned me. with had some legislation, there's been controversy but there's also the ability for, we don't have a payer here. but the researcher and the regulator and the payer, to communicate that for -- before something comes. the payers at the state level certainly, the medicaid payers were not ready for what was happening. they have been prohibited from having those discussions because of the laws. i'm hopeful that we were able to do some thing, particularly gene therapy or gen

. >> reporter: scott gottlieb is e commissioner of the u.s. food and drug administration.e says while e-cigarettes can be used by adults to stop smoking, it can't be done at the expensof children. >> if all we do is end up hooking a whole generation of young people on nicotine by making these products available, we won't have done a service from a public health standpoint. so we need to be very aggressive in trying to take steps to crackdown, prevent the youth use of the products. >> reporter: the f.d.a. is being thed by several organizations tre challenging gottlieb's decisiallow e-cigarettes, to remain on the markethuntil 2022, t regulatory review. gottlieb says they needed time to set comprehensive standards for all these products, not just juul. ac we also can't be playing a-mole, just going after one particular product and don't have in place rules that address the overall category. >> reporte the f.d.a. has requested internal research from e-cigarette companies,ncluding why these products are so pular with kids. they are conducting a nationwide, undercover blitz to s

on c-span3, fda commissioner scott gottlieb testifies before a house subcommittee. in the afternoon, secretary of state mott pompeo discusses president trump's meetings with the president north korea. that is live at 3:00 p.m. eastern. former fox news acre who is also the ceor was joined by of the group at the national press club to discuss recent changes to the nearly 100-year-old competition. this runs about one hour. >>> to follow the discussion long on twitter using the hashtag mpc live if the if you're in our audience in house our ave questions for speaker, you'll find cards on your table. and e write your questions pass them to the gentleman here who will bring them you to the stage. >>> i would also like to acknowledge additional members of the team who are responsible organizing today's event. --addition to kevin, we have especially lindsey underwood, mccaron.r, and bill guests today both of hom are looking to give the miss america program a make overto accurately reflect modern american women. crowned carlson who was miss america herself started her reporte

on c-span3, fda commissioner scott gottlieb testifies before a house subcommittee. in the afternoon, secretary of state mott pompeo discusses president trump's meetings with the president north korea. that is live at 3:00 p.m. eastern. former fox news acre who is also the ceor was joined by of the group at the national press club to discuss recent changes to the nearly 100-year-old competition. this runs about one hour.

we were doing immunologic tests, and within six months of michael gottlieb's discovery of aids, we found women and children who had the same symptomatology and we felt that they were also aids. so it told us that this was being transmitted probably by a virus -- we didn't know what the virus was in '81, '82 -- and that it was transmitted by blood transfusions, which we found the first case of here in san francisco, and then from mothers to infants. and that expanded the idea of what was gonna happen in this epidemic. and it was really dreadful, and we used to think what would happen if this epidemic expanded. >> and i remember meeting some of the children who were infected. unfortunately, they all died very young, because there wasn't any treatment for them. the treatments were hard enough to get for the adults. >> well, it was urgent. i mean, basically, the young men with aids were dying -- there was no treatment until 1987 -- from 1981 to '87. and for children, it was hard to explain, and for the first time i think in medical history, modern medical history anyway, we had a disease tha

scott gottlieb about these concerns and he agrees. dr. gottlieb agreed to quickly issue guidance and develop regulations to provide clarity on what difficult to study means and that we do not change the gold standard of the food and drug administration's drug approval process. also conditional approval is not available for antimicrobial drugs. the language in the bill is clear, and dr. gottlieb understands the conditional be approval is not available for antimicrobial drugs. congress will also conduct oversight to make sure conditional approval is achieving the goal of helping more vets and keeping our food supply safe. this bipartisan legislation will help keep animals healthy, prevent disease outbreaks and protect our food supply. so, mr. president, i ask unanimous consent that the senate proceed to the immediate consideration of h.r. 5554. the presiding officer: the clerk will report. the clerk: h.r. 5554, an act to amend the federal food, drug and cosmetic pact and so forth. the presiding officer: is there objection to proceeding to t

uniform girls will now have to wear plain trousers just like boys what do you think about this story gottlieb use only the word well it seems the reasons differ from school to school why they're doing this so my hope to implement a more gender neutral policy simply others hope to make life easier for the small but increasing number of transgender students one schools even cited fears over the sexualization of young women this illustrates fix the length of skirt that we want a lot of the students are wearing skirts too short and that is why we are moving towards just trousers for girls in september. not everyone's except to the new policies the one parent we spoke to was floored that the school had actually asked the parents opinion before making these changes to the uniform. i was very shocked . there was no colorful way that it parent so. for the bar no reason to get there what so far i can speak for an avowal and a number of her classmates and i know the children at school to know what to wear trousers all the time they should be given the choice to take away the choice is wrong. well petit

that i've raised these issues at hearings and in conversations with the fda commissioner, scott gottlieb, and i am very impressed with him. he agrees that the current system is too complex. it is opaque, and at times it seems to be designed to benefit everyone except the patient. the commissioner is especially passionate about redesigning the rebate structure to ensure that savings are passed on to those who need them most, patients and their families. he has announced that the fda will expedite generic entry for cases with a limited competition, and he has stated his commitment to increasing competition over all, which is very encouraging. i'm also encouraged that in congress at a time when bipartisanship seems like an increasingly rare commodity, that this is an issue that can bring us together. while the lion's share of work remains to be done, the multitude at hearings, letters, bills and milestones so far demonstrate a pattern of working together and across the aisle to help reduce the cost of prescription drugs. if we want new medicines to reach consumers who need them, the compani

the fda under scott gottlieb is pushing more genetics -- more on the market.e same thing as drugs that are already out there that are very expensive and going to bring the cost down. jillian: why is it taken this long to get to this point? >> interesting question and the answer is we have an entitlement, an insurance company doing a deal behind-the-scenes with drug manufacturing. you don't know what the prices and we saw headlines the last couple years where some companies gouged prices and things like epipen zoomed up in price and under those circumstances, may end up allowing importation of drugs and if you gouge patients we will bring it in from another country which is cheaper but we didn't know what these things cost. the prices are hidden from us. jillian: now we are more aware. >> the president is reading these things are rebelling and the hhs secretary is on it. we will see an impact. competition being key, price transparency being key. jillian: talk about the difference this makes in the lives of patients on medication every day, might be on medicatio

on c-span3, fda commissioner scott gottlieb testifies.

commissioner scott gottlieb explained the move, saying that the agency's current standards for milk referenceroducts from lactating animals. and, "an almond doesn't lactate." ( laughter ) it does if you're doing it right. >> jon: yeah, yeah! >> stephen: that means nothing. that means nothing. that has no meaning. don't parse that joke. ( laughter ) by the way, the first person to seamlessly work the phrase "an almond doesn't lactate" into their wedding vows and sends me a video gets-- i don't know-- a t-shirt. tell you what, we'll send you -- we'll send you this t-shirt. ( cheers and applause ) >> jon: lactose tolerance. ( piano riff ) ( applause ) >> stephen: and i urge you not to do it. ( laughter ) now this may seem silly, but there's a lot of lobbying around this issue, and if it happens, it will be a major boon for dairy groups, which have been struggling amid dropping prices and global oversupply. in fact, they've been having such a rough time that they had to change their slogan from "got milk?" to "we've got way too much milk! please buy more milk! it's good for hair maybe?" ( laughte

in the advertising words and doesn't cheng the fact he was ousted from his job, and -- orer lynn gottlieb, another character who is head of -- was the head of group m, the largest media buying agency, stepped down. i predict head would. he said he would but i don't think people leaving dates the book. at least i don't feel that way. obviously some people do. so. >> one perspective of looking at the book, why this is a book that started about advertising and marketing, to why i encourage people to read it, is it affects all industries because to a great extent, many of the characters -- he's going to forget how some of the characters don't exist miami -- exist anymore -- >> i want to forget everything. i'm moving on to another planet. >> so you have the are -- martin sorrell who founds the world's largest 150,000 person holding company by buying a wire and plastic company as a shell company, and over the last 25-30 years, has formed this huge corporation. he does not have his job. the person who actually created what is likely to be the most important media operation in the world, which is

on c-span3 scott gottlieb testifies before a house subcommittee.n the afternoon secretary of state mike pompeo briefs the senate foreign relations committee on donald trump's meetings with the leaders of russia and north korea live at 3:00 eastern. join washington journal friday live in baltimore, maryland as we spotlight the opioid epidemic, we look at how city and state agencies work with city residents who are addicted to opioids. baltimore city health department commissioner of health on the challenges large cities like baltimore face dealing with opioid abuse. and maryland opioid to operational command center on efforts the state is making to counter opioid abuse. maryland democratic congressman elijah cummings talks about his effort along with elizabeth warren to direct $100 billion

testimony from scott gottlieb and nih director francis collins tomorrow morning starting at 9:00 a.m. eastern. tomorrow afternoon, secretary of state mike pompeo will testify on north korea, president trump's trip to the nato summit, and the president's meeting with russian president vladimir putin. mr. pompeo will testify before the senate foreign relations committee at 3:00 eastern, also live here on c-span3. >>> supreme court nominee brett kavanaugh continues to meet with senators on capitol hill. follow the confirmation process on c-span leading up to the senate confirmation hearings and the vote. watch live on c-span. watch any time on c-span.org, or listen with the free c-span radio app. >>> former fox news anchor gretchen carlson, who is also former miss america is now the chair of the miss america board. she was joined by the group's ceo at the national press club to discuss the recent changes to the nearly 100-year-old competition. this runs about an hour. >> good afternoon and welcome to the national press club. the place where news happens. i'm angela keen, deputy editor of

on wednesday, we are having a conversation with scott gottlieb. similars and we have an outstanding panel of three experts to react to his remarks. that's going to be on wednesday afternoon at one -- 1:30. at the end of the week, we have a conference on the experience to remember what mips stands for. those who remember know it very well. we have policy options to discuss its shortcomings. let me introduce mark hall. [applause] that makes my slides project. oh, there they are. thank you very much. a quite interesting project and i appreciate the support we've gotten from the tookings institution administer the program and also to the leader in generating the structure to allow me to do this work. as you look over the ark of five years or so of open enrollment, once the web problems were dealt with, there was a good amount of competition in most states. carriers,arriers, new and prices were remarkably low. it turns out they were underpriced. the market was pretty vibrant for the most part. trouble started to emerge in 2016 as carriers realize they

or commissioner gottlieb of f.d.a. could come up with a plan for the importation of safe prescription drugs from canada and other trusted countries. so, madam president, consumers today are promised the sun, the moon, and the stars if they will simply get a prescription filled. senator durbin and i want to improve transparency in prescription drug advertisement so that consumers can decide for themselves. our amendments would simply clarify that the secretary of h.h.s. has the authority to require drug companies to report the list price on advertisements. and i had a telephone conversation this morning with that secretary of h.h.s. at his instigation, and he suggested that this would be very helpful, not only for him to accomplish the goals that he wants to, but to carry out the president's blueprint. one of several steps in that blueprint to get the price of pharmaceuticals down for the consumer. consumers know the price of every other item they purchase before they make their decision. just think what of a benefit it

gottlieb, throughout several comments -- but there was really ofdata support on the value precision,editing. there's no data presented. host: can you explain for those that don't follow this and don't have a background in medicine about gene therapy? when they hear that word, what are doctors talking about? what our researchers talking about? caller: well, i'm a surgeon, but generally what they talk about is that they want to look at the cells.tent of cancer cancer cells have something wrong with the dna. right now we can monitor and record the dna. cells and to tumor there may be something that sticks out, that there is a medication to specifically target that specific defect. that is what he's talking about, the ramifications. these are dna defects. so drug companies have, for a long time, used clinical trials to determine what drug will work with a group of people. but you look at the individual level and you have a look at finding a drug for each individual. that is precision. that is certainly a more expensive approach. think, as ao you surgeon, about the nih efforts with their

on wednesday, we're having a conversation with scott gottlieb, fda commissioner, about biosimilars, and have an outstanding pam of three experts to react to his remarks. that's going to be wednesday afternoon at 1:30. also at the end of the week, we have a conference on the experience with mipps. i can't remember what it stands for. but those that are interested know it very well. and experience with mips to date and the policy options to address its shortcomings. so without further ado, let me into deuce ma-- introduce mark . [ applause ] >> thank you very much. it's been a quite interesting project and i appreciate the support that we've gotten from the brookings institution, as well as robert wood johnson, and advisers at the academy to administer the program and thanks to dick nathan who, again, was a real leader in generating the structure that allowed me to do this work. so as you look over this the arc of five or so years of open enrollment, things got off to a bad start with the web problems, but once dealt with, there was a good amount of competition in most states. existing ca

testimony from scott gottlieb and nih director francis collins tomorrow morning starting at 9:00 a.m. eastern. tomorrow afternoon, secretary of state mike pompeo will testify on north korea, president trump's trip to the nato summit, and the president's meeting with russian president vladimir putin. mr. pompeo will testify before the senate foreign relations committee at 3:00 eastern, also live here on c-span3. >>> supreme court nominee brett kavanaugh continues to meet with senators on capitol hill. follow the confirmation process on c-span leading up to the senate confirmation hearings and the vote. watch live on c-span. watch any time on c-span.org, or listen with the free c-span radio app. >>> former fox news anchor gretchen

on c-span three fda commissioner scott gottlieb testifies before a house subcommittee. afternoon, secretary of state mike pompeo briefs the senate foreign relations committee on president trump's meetings with the leaders of russia and north korea area that is live at 3:00 p.m. eastern. afterwards,ght on former white house press secretary sean spicer discusses his book "the briefing: politics, the press, and the president." he is interviewed by michael steele. and donaldeagan trump are about 180 degrees apart from each other. yet here we are in this space. how did you navigate that? we are both reagan conservatives in that regard. , yout a little bit of a know, a dance every once in a while? how did you do it? >> with respect to the president, there is no question, he is not traditional in terms of how he speaks. but he also k'nex to people in a way that most politicians never have. he talks very bluntly. wonn't think he would have the presidency if it weren't for that style. there is a balance with elected officials, which is, they say all the right wings but they don'

we are already moving forward on that and commissioner gottlieb is just recently put guidance out to create a better pathway for sharing of information and discussions between pharmaceutical manufacturers and insurers around economic information in the plan for new product launches so they can collaborate and build those value -based treatments as quickly as possible. we are working on guidancee around reporting and a kickback statute roles that can again create a greater pathway around how we private actors set up the value -based range was there. it's a feature of how we do pay for drugs and paper outcomes for healthcare and brinkley, i love to see it if theymo can be more incorporated into the overall holistic health of the patient and more of a bundled notion and that is probably long-term in the future rather than a payment on the drug itself. >> what actions do you need from us on the side of the dais tosu enable you to implement these value -based pricing to ensure that spinning for healthcare services and products are in line to overall healthcare cost? >> i believe we have t

on c-span3, fda commissioner scott gottlieb said the for house subcommittee and that is five and 9 am eastern and then in the afternoon secretary of state mike pompeo breves foreign relations committee on president trump's meetings with the leaders of russia and north korea. that is live at 3 pm eastern. c-span's washington journal, live every day with news and policy issues that impact you. coming up wednesday morning, from statuary hall and the capital, members of the agriculture committee from both sides of the aisle discuss how president trump's trade and tariff policies are impacting their bottom lines. on the program, kansas republican congressman roger marshall, massachusetts democratic congressman and subcommittee on nutrition member james montgomery and senator and agriculture nutrition and forced committee member steve baines. be sure to watch c-span's washington journal, live at 7 eastern, wednesday morning, join the discussion. saturday at 10 am eastern on american history tv. live all day coverage of the confederate conference but from james madison university in harrison

on c-span3, fda commissioner scott gottlieb testifies.ing up next, a look at the impact of tariffs on u.s. agriculture and the administration's plan to help farmers. coming upwe're joined by membere house-senate agriculture committees, and alan beer gut. washington journal is live now. host: good morning, it is wednesday, july 25, 2016. a busy day on capitol hill will include secretary of state mike pompeo's afternoon good morninge before the senate foreign relations committee amid ongoing fallout from president trump's summit last week, with russian president vladimir putin. we will begin on the washington journal with a new plan from the trump administration to spend $12 billion in emergency aid. we will be talking with members of the house and senate agriculture committee's about this topic later this morning, but for now we will start with hearing from you. if you are a farmer or in the agriculture industry, you can call in at (202) 748-8000. all others can call in at (202) 748-8001. you can also catch up with us on social media. @csp

from scott gottlieb and dr. francis collins. they willp they will be speaking about efforts to accelerate cancerp congress passed thecongress passed the 21st century curescures actp cures act whichcures act which was decide to advanceadvancep advance medical research. >>> our guests can take their seat. recognize myself five minutes for an opening statement. this morning certainly i want to welcome our witnesses.